NCT05813717View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986325

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

90630

Local Institution - 0001, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05813717 - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter